Roivant Sciences Ltd.
Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.
Sukhatme Mayukh (President & CIO) sold 335,174 shares of Roivant Sciences Ltd. (ROIV) at an average of $36.88 ($36.48–$37.30, $12.36M total) across 3 trades over 2026-08-19 to 2026-08-21.
Sukhatme Mayukh (President & CIO) sold 664,826 shares of Roivant Sciences Ltd. (ROIV) at an average of $36.34 ($36.23–$37.18, $24.16M total) across 4 trades over 2026-08-14 to 2026-08-18.
Over the past 7 days, alphai's AI scored 1 news story mentioning ROIV (Roivant Sciences Ltd.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ROIV coverage spans insider activity, regulation and earnings.
In the last 30 days, ROIV insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($36.5M). The most active reporter was Sukhatme Mayukh, President & CIO, with 7 filings.
Approval opens a new orphan‑drug market, likely lifting ROIV stock.
Large insider sell may signal negative sentiment, potential short-term pressure on ROIV.
The filing is a routine insider sale with no stated 10b5-1 plan, which can modestly affect near-term sentiment but does not change fundamentals by itself.
Near-term trading focus is on the credibility of clinical timelines and cash runway into profitability, plus the Moderna settlement cash inflow.
This is a routine, pre-planned insider sale with disclosed size and price, offering limited incremental signal beyond positioning/liquidity.
alphai scores every news story that mentions ROIV with an AI model for sentiment and relevance, and aggregates insider trades from Roivant Sciences Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.
3 min readSukhatme Mayukh (President & CIO) sold 335,174 shares of Roivant Sciences Ltd. (ROIV) at an average of $36.88 ($36.48–$37.30, $12.36M total) across 3 trades over 2026-08-19 to 2026-08-21.
1 min readSukhatme Mayukh (President & CIO) sold 664,826 shares of Roivant Sciences Ltd. (ROIV) at an average of $36.34 ($36.23–$37.18, $24.16M total) across 4 trades over 2026-08-14 to 2026-08-18.
2 min readRoivant Sciences Ltd. (ROIV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update • Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track for launch by the end of September 2026; topline data from P
6 min readVenker Eric (President & Immunovant CEO) sold 200,000 shares of Roivant Sciences Ltd. (ROIV) at $34.95 ($6.99M total) on 2026-07-27 under a Rule 10b5-1 trading plan.
1 min readArbutus Biopharma (ABUS) and Genevant Sciences, a Roivant unit, filed three international patent lawsuits against Pfizer and BioNTech to enforce LNP patents tied to mRNA-LNP COVID-19 vaccines, seeking monetary relief and injunctions. Arbutus said it received about $178 million from Moderna under a settlement and expects a Genevant-parent dividend in Q3 2026, plus share repurchases up to about $230 million starting Q3 2026.
4 min readEpperly Melissa B, sold 17,750 shares of Roivant Sciences Ltd. (ROIV) at an average of $34.38 ($34.32–$34.71, $0.61M total) across 2 trades on 2026-06-29 under a Rule 10b5-1 trading plan.
2 min readMANCHESTER KEITH S sold 200,000 shares of Roivant Sciences Ltd. (ROIV) at $35.45 ($7.09M total) on 2026-06-30.
2 min readMANCHESTER KEITH S sold 1,438,163 indirectly-held shares of Roivant Sciences Ltd. (ROIV) at an average of $34.32 ($33.92–$35.28, $49.35M total) across 5 trades over 2026-06-26 to 2026-06-30.
2 min readGold Daniel Allen sold 1,438,163 indirectly-held shares of Roivant Sciences Ltd. (ROIV) at an average of $34.32 ($33.92–$35.28, $49.35M total) across 5 trades over 2026-06-26 to 2026-06-30.
2 min read